万维书刊网微信二维码

扫微信,关注编辑QQ!

您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生2>>血液学
您的位置:万维书刊网 >>sci/e期刊大全 >>医药卫生1>>外周血管病

Clinical and Applied Thrombosis/Hemostasis(或:CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS)《临床与应用血栓/止血》 (官网投稿)

简介
  • 期刊简称CLIN APPL THROMB-HEM
  • 参考译名《临床与应用血栓/止血》
  • 核心类别 SCIE(2024版), 知网外文库,外文期刊,
  • IF影响因子
  • 自引率6.40%
  • 主要研究方向医学-HEMATOLOGY血液学;PERIPHERAL VASCULAR DISEASE外周血管病

主要研究方向:

等待设置主要研究方向
医学-HEMATOLOGY血液学;PERIPHERAL VASCULAR DISEASE外周血管病

Clinical and Applied Thrombosis/Hemostasis《临床与应用血栓/止血》(年刊). Clinical and Applied Thrombosis/Hemostasis (CATH) is an open access, peer reviewed jo...[显示全部]
征稿信息

万维提示:

1、投稿方式:在线投稿。

2、期刊网址:https://journals.sagepub.com/home/cat

3、投稿网址:https://mc.manuscriptcentral.com/cath

4、官网邮箱:sheilaplatt@optonline.net(编辑部)

5、期刊刊期:年刊,一年出版1期。

2022119日星期三

                              

 

投稿须知【官网信息】

 

Clinical and Applied Thrombosis/Hemostasis

Manuscript Submission Guidelines:

This Journal is a member of the Committee on Publication Ethics.

This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).

Please read the guidelines below then visit the journal’s submission site https://mc.manuscriptcentral.com/cath to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned.

SAGE Publishing disseminates high-quality research and engaged scholarship globally, and we are committed to diversity and inclusion in publishing. We encourage submissions from a diverse range of authors from across all countries and backgrounds.

Only manuscripts of sufficient quality that meet the aims and scope of Clinical and Applied Thrombosis/Hemostasis will be reviewed.

As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.

If you have any questions about publishing with SAGE, please visit the SAGE Journal Solutions Portal

Please note: Beginning January 1, 2022 the APC for CAT will be $2400 USD. This APC will apply to papers with original submission dates of Jan 1, 2022 onward.

Please Read the Manuscript Submission Guidelines below before submitting your manuscript here:

1. Open Access

Clinical and Applied Thrombosis/Hemostasis is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.

For general information on open access at SAGE please visit the Open Access page or view our Open Access FAQs.

2. Article processing charge (APC)

If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable. This APC covers the cost of publication and ensures that your article will be freely available online in perpetuity under a Creative Commons licence.

Please note: Beginning January 1, 2022 the APC for CAT will be $2400 USD. This APC will apply to papers with original submission dates of Jan 1, 2022 onward.

3. What do we publish?

3.1 Aims & scope

Before submitting your manuscript to Clinical and Applied Thrombosis/Hemostasis, please ensure you have read the Aims & Scope.

……

更多详情:

https://journals.sagepub.com/author-instructions/CAT


  • 万维QQ投稿交流群    招募志愿者

    版权所有 Copyright@2009-2015豫ICP证合字09037080号

     纯自助论文投稿平台    E-mail:eshukan@163.com


投稿问答最小化  关闭